Jan Meulen

Company: Obsidian Therapeutics

Job title: Chief Scientific Officer

Seminars:

Engineering an IL2-Free, Potent & Persistent TIL With Regulated Membrane-Bound IL15 12:30 pm

• Sidestepping capillary leak syndrome associated toxicity and Treg effects • Removing the need for toxic and costly IL2 therapy associated with conventional TILs • Uncovering clinical potential as a novel TIL product with enhanced safety and efficacyRead more

day: Day Two